Iovance Biotherapeutics Inc (IOVA) FinancialsIOVAIovance Biotherapeutics Inc

Evaluating the bottom line, Iovance Biotherapeutics Inc maintains a gross margin of 46.54%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -52.26%, while the net margin is -47.64%. These profitability ratios, combined with a Return on Equity (ROE) of -40.36%, provide a clear picture of how effectively IOVA converts its operational activities into shareholder value.

In the context of the broader market, IOVA competes directly with industry leaders such as ABCL and RCUS. With a market capitalization of $3.76B, it holds a significant position in the sector. When comparing efficiency, IOVA's gross margin of 46.54% stands against ABCL's 100.00% and RCUS's 100.00%. Such benchmarking helps identify whether Iovance Biotherapeutics Inc is trading at a premium or discount relative to its financial performance.

Iovance has shown substantial revenue growth, with Q2 2026 revenue at $99.3 million, up 66% year-over-year. The gross margin has improved to 46.54%, indicating better profitability. However, the company is still reporting net losses, with a net income of -$47.3 million in Q2 2026.